| Public | Nasdaq:BDSI |
| Date | 7/02 |
| Raised | |
| Post IPO Valuation |
| POST IPO FUNDING | |
| Post IPO Equity, 11/12 | $40M |
BioDelivery Sciences (“BDSI”®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA®) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
